Just days after Democratic U.S. Senate nominee Phil Bredesen announced a proposal he said would reduce the price that Americans pay for prescription drugs, President Donald Trump is outlining a similar idea.

On Thursday, the Republican president said his administration will make several changes that will ultimately lower the cost of prescription drugs in the United States, including invoking what is known as the "most favored nations" clause.

The clause ensures a seller gives a buyer the best terms for something available to others. That would mean that drug companies selling prescriptions to the United States would need to offer them at the same price as they do for other countries.

"This is a change for the people," Trump said at a news conference.

On Oct. 16, Bredesen called for the nation to invoke the clause, suggesting that it was an extension of Trump's "America first" approach to governing.

When Bredesen announced his proposal, a spokeswoman for his opponent, Republican nominee Marsha Blackburn, slammed the former governor.

“(Bredesen) claims he wants to sit down with President Trump, but he didn’t even want him to be president," Blackburn spokeswoman Abbi Sigler said at the time. "He gave $33,400 to elect Hillary Clinton and urged Tennesseans to roll up their sleeves and get to work to elect her. This is just another phony political stunt.”

Trump said Thursday the changes he was making, which also include allowing the federal government to negotiate prices for certain drugs, would be "revolutionary."

"In every action we take, we are putting America first," Trump said. "And this is very much about putting America first."

Another component of the president's plan includes changing a current practice that results in some doctors and hospitals receiving financial incentives to prescribe high-priced drugs.

The president's plan also seeks to create an "international pricing index," which would be a benchmark to decide how much the government should pay for drugs purchased under Medicare Part B, according to The New York Times.

Sigler, Blackburn's spokeswoman, said on Thursday that the Brentwood congressman was "working on medical transparency and accountability issues" before Bredesen entered the race. Sigler also renewed criticism of Bredesen for supporting government-run health care, tax increases and donating to Clinton.

Responding to Trump's announcement, Laura Zapata, communications director for Bredesen's campaign, said in a statement that Bredesen's plan "illustrates what he's said from day one — he will work with President Trump to get things done for Tennesseans because that's what Senators ought to do."

Zapata reiterated criticism of Blackburn, saying she has a cozy relationship with pharmaceutical companies, noting the congressman has received more than $800,000 in contributions from the industry.

The president's proposal comes as Tennesseans continue to flock to the polls during early voting, which ends Nov. 1.

Blackburn, who Trump endorsed and supported by visiting Tennessee, and Bredesen are in a tight race ahead of the Nov. 6 general election.

Reach Joel Ebert at jebert@tennessean.com or 615-772-1681 and on Twitter @joelebert29.